John Crown, Chair of Translational Cancer Medicine at Dublin City University, shared a post on X:
“Tebebtafusp is the 1st drug to show overall survival advantage in metastatic uveal (eye) melanoma.
We gave the first dose outside of compassionate access last week.
Sadly-now the latest example of 2Tier care. Not available in HSE.”
Patrick Forde, Professor at Johns Hopkins University and Co-Director of the Division of Upper Aerodigestive Malignancies at the Sidney Kimmel Comprehensive Cancer Center, reshared the shared a post on X, adding:
“As NI follows NHS England, several key cancer treatments are available in Derry but not in Donegal etc.
It’s a complex q but Ireland is near bottom of the table in treatment access.
The govt has expressed an interest in improving the situation.”
More posts featuring Patrick Forde.